Kaleido Biosciences, Inc. has decided to halt work on a planned Phase 2 chronic obstructive pulmonary disease (COPD) study and terminate its agreement with the COPD Foundation. These decisions were made in order to re-align resources and focus the company's efforts.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.0001 USD | 0.00% | 0.00% | 0.00% |
2022 | Kaleido Biosciences, Inc.(NasdaqGS:KLDO) dropped from S&P Global BMI Index | CI |
2022 | Kaleido Biosciences, Inc.(NasdaqGS:KLDO) dropped from S&P TMI Index | CI |
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
0.00% | 4.26K | |
+33.63% | 50.93B | |
-0.09% | 42.12B | |
+49.62% | 42.05B | |
-4.96% | 29.18B | |
+11.18% | 26.02B | |
-21.95% | 18.9B | |
+8.61% | 13.21B | |
+24.73% | 12.17B | |
+28.31% | 12.16B |
- Stock Market
- Equities
- KLDO Stock
- News Kaleido Biosciences, Inc.
- Kaleido Biosciences, Inc. Decides Halt Work on a Planned Phase 2 Chronic Obstructive Pulmonary Disease Study